SalvaRx Group plc discovers and develops immune-oncology drugs.
Solid track record and fair value.
Share Price & News
How has SalvaRx Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: SALV underperformed the UK Biotechs industry which returned 26.6% over the past year.
Return vs Market: SALV underperformed the UK Market which returned 2.5% over the past year.
Price Volatility Vs. Market
How volatile is SalvaRx Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most SalvaRx Group plc (LON:SALV) Stock?
1 year ago | Simply Wall StWho Are The Major Shareholders In SalvaRx Group plc (LON:SALV)?
1 year ago | Simply Wall StShould You Be Concerned About SalvaRx Group plc's (LON:SALV) Shareholders?
Is SalvaRx Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: Insufficient data to calculate SALV's fair value to establish if it is undervalued.
Significantly Undervalued: Insufficient data to calculate SALV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SALV is good value based on its PE Ratio (0x) compared to the Biotechs industry average (32.2x).
PE vs Market: SALV is good value based on its PE Ratio (0x) compared to the UK market (16.4x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate SALV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SALV is good value based on its PB Ratio (0.3x) compared to the GB Biotechs industry average (1.7x).
How is SalvaRx Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SalvaRx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether SalvaRx Group is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- SalvaRx Group competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has SalvaRx Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SALV's earnings have grown significantly by 103.5% per year over the past 5 years.
Accelerating Growth: SALV's earnings growth over the past year (6826.7%) exceeds its 5-year average (103.5% per year).
Earnings vs Industry: SALV earnings growth over the past year (6826.7%) exceeded the Biotechs industry -2.3%.
Return on Equity
High ROE: SALV's Return on Equity (1074.8%) is considered outstanding.
Return on Assets
ROA vs Industry: SALV has a higher Return on Assets than the Biotechs industry average last year.
Return on Capital Employed
ROCE Improving: SALV is currently unprofitable, so its Return on Capital Employed is negative.
How is SalvaRx Group's financial position?
Financial Position Analysis
Short Term Liabilities: SALV's short term assets (£2.1M) exceeds its short term liabilities (£1.1M)
Long Term Liabilities: SALV has no long term liabilities
Debt to Equity History and Analysis
Debt Level: SALV's debt to equity ratio (14.5%) is considered satisfactory
Reducing Debt: Insufficient data to determine if SALV's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SALV's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if SALV's interest payments on its debt are well covered by EBIT.
Inventory Level: SALV has a low level of unsold assets or inventory.
Debt Coverage by Assets: SALV's debt is covered by short term assets (assets are 2.552310x debt).
What is SalvaRx Group's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate SALV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SALV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if SALV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SALV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SALV's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
What is the CEO of SalvaRx Group's salary, the management and board of directors tenure and is there insider trading?
SalvaRx Group has no CEO, or we have no data on them.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Denham Hervey Eke (67yo)
CFO & Director
- Tenure: 0.8yrs
Greg Bailey (63yo)
Non Executive Director
- Tenure: 0yrs
Jim Mellon (62yo)
Non Executive Chairman
- Tenure: 0yrs
Denham Hervey Eke (67yo)
CFO & Director
- Tenure: 0.8yrs
SalvaRx Group plc's company bio, employee growth, exchange listings and data sources
- Name: SalvaRx Group plc
- Ticker: SALV
- Exchange: AIM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£1.651m
- Shares outstanding: 36.70m
- Website: https://www.salvarx.io
Number of Employees
- SalvaRx Group plc
- Commerce House
- 1 Bowring Road
- IM8 2LQ
- Isle of Man
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SALV||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Mar 2016|
|N3LN||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||Mar 2016|
|SLVA.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Mar 2016|
SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/06 23:02|
|End of Day Share Price||2019/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.